Encyclopedia entry
Compounded vs licensed GLP-1
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last updated 2026-05-22
Compounded GLP-1 is semaglutide or tirzepatide active ingredient mixed into custom formulations by a non-manufacturer, typically a specialist compounding pharmacy. In the US, compounded GLP-1 was widely available during 2023 to 2024 when FDA shortage lists allowed it. In the UK, compounded GLP-1 is not part of routine authorised supply: unlicensed compounding is limited to bespoke "Specials" prepared for an individual patient's clinical need under strict regulatory exemptions, not routine commercial supply. PeptideClear does not list or recommend compounded sources.
What "licensed" means in the UK
Licensed UK GLP-1 medications are tirzepatide (Mounjaro, Eli Lilly), semaglutide (Wegovy and Ozempic, Novo Nordisk), and liraglutide (Saxenda and Victoza, Novo Nordisk). Each holds a UK MHRA marketing authorisation and is supplied in pre-filled pens or single-use vials manufactured by the licence holder. Cold-chain logistics from manufacturer to UK pharmacy are validated and documented.
Why compounded is not legal UK supply
- · Compounded mixtures are unlicensed medicinal products under the Human Medicines Regulations 2012.
- · UK Specials manufacturing licence is needed to prepare unlicensed medicines, and is granted for specific patient needs, not routine supply.
- · The active ingredient source matters: licensed manufacturers produce semaglutide and tirzepatide to GMP standard with full chain of custody. Compounded sources may not have this.
- · MHRA enforcement focus 2024 onwards has targeted UK retailers and pharmacies offering compounded supply.
What to verify before purchase
A UK pharmacy supplying GLP-1 should be able to confirm: GPhC registration number, the medication brand name (Mounjaro or Wegovy or Saxenda, not "semaglutide compound"), the manufacturer (Eli Lilly or Novo Nordisk), batch number traceability, and validated cold-chain delivery. If a supplier is vague on any of these, the product is unlikely to be licensed UK supply.
Licensed vs compounded GLP-1 at a glance
| Feature | Licensed UK GLP-1 | Compounded GLP-1 |
|---|---|---|
| UK regulatory status | Holds an MHRA marketing authorisation | Unlicensed medicinal product under the Human Medicines Regulations 2012; not routine authorised UK supply |
| Examples | Mounjaro, Wegovy, Ozempic, Saxenda, Victoza | Custom-mixed "semaglutide compound" or "tirzepatide compound" |
| Manufacturer | Licence holder (Eli Lilly, Novo Nordisk), GMP standard | A non-manufacturer or compounding pharmacy; source may not be GMP |
| Chain of custody | Full batch traceability and validated cold chain | Often unclear or undocumented |
| UK legal route | Standard licensed-medicine prescription and dispensing | Limited to bespoke "Specials" for an individual clinical need under strict exemptions, not routine commercial supply |
Editorial commentary on the UK regulatory position. PeptideClear does not list, source, or recommend compounded GLP-1. Your prescriber and a GPhC-registered pharmacy handle legitimate supply.
Frequently asked questions
Is compounded GLP-1 available in the UK?
Not as routine authorised supply. Compounded mixtures are unlicensed medicinal products under the Human Medicines Regulations 2012. Unlicensed compounding in the UK is limited to bespoke "Specials" prepared for an individual patient's clinical need under strict regulatory exemptions, not routine commercial supply. PeptideClear does not list or recommend compounded sources.
How can I tell if a GLP-1 supplier is legitimate?
A legitimate UK pharmacy should confirm its GPhC registration number, the medication brand name (Mounjaro, Wegovy, or Saxenda rather than "semaglutide compound"), the manufacturer (Eli Lilly or Novo Nordisk), batch traceability, and validated cold-chain delivery. Vagueness on any of these is a warning sign that the product is not licensed UK supply.
Why does the active ingredient source matter?
Licensed manufacturers produce semaglutide and tirzepatide to GMP standard with full chain of custody. Compounded sources may not, which is why MHRA enforcement from 2024 onwards has targeted UK retailers and pharmacies offering compounded supply.
Related: MHRA medicines classification · cold chain · UK pharmacies.